Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ruane

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Gastroenterology|July 31, 2018
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver DiseaseRohit Loomba, Zeid Kayali, Mazen Noureddin, et al.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
AIDS and Behavior|July 12, 2026
Implementation Journey with CAB LA for PrEP Among Men Who Have Sex with Men and Transgender Men: Insights from the PILLAR Trial Through 12 MonthsNanlesta Pilgrim, Hadrian Holder, Julian A Torres, et al.
The Lancet. HIV|September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialPedro Cahn, Richard Kaplan, Paul E Sax, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 StudyJürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Hepatology (Baltimore, Md.)|November 10, 2020
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHRohit Loomba, Mazen Noureddin, Kris V Kowdley, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Gastroenterology|July 31, 2018
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver DiseaseRohit Loomba, Zeid Kayali, Mazen Noureddin, et al.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
AIDS and Behavior|July 12, 2026
Implementation Journey with CAB LA for PrEP Among Men Who Have Sex with Men and Transgender Men: Insights from the PILLAR Trial Through 12 MonthsNanlesta Pilgrim, Hadrian Holder, Julian A Torres, et al.
The Lancet. HIV|September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialPedro Cahn, Richard Kaplan, Paul E Sax, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 StudyJürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
Hepatology (Baltimore, Md.)|November 10, 2020
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHRohit Loomba, Mazen Noureddin, Kris V Kowdley, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Pageof 4